e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term effect of a
1
-antitrypsin augmentation therapy on the decline of FEV
1
in deficient patients: an analysis of the AIR database
Iris G.M. Schouten, Marise J. Kasteleyn, Roula Tsonaka, Robert Bals, Alice C. Turner, Ilaria Ferrarotti, Angelo G. Corsico, Beatriz Lara, Marc Miravitlles, Robert A. Stockley, Jan Stolk
Source:
ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Iris G.M. Schouten, Marise J. Kasteleyn, Roula Tsonaka, Robert Bals, Alice C. Turner, Ilaria Ferrarotti, Angelo G. Corsico, Beatriz Lara, Marc Miravitlles, Robert A. Stockley, Jan Stolk. Long-term effect of a
1
-antitrypsin augmentation therapy on the decline of FEV
1
in deficient patients: an analysis of the AIR database. ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
Source: Virtual Congress 2021 – Treatments for airway diseases
Year: 2021
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis
Source: International Congress 2017 – Asthma management
Year: 2017
CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Annual FEV1% variation before and after augmentation therapy in severe alpha-1-antitrypsin deficiency
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Reducing the decline of FEV
1
after a 4-year therapy with montelukast in patients with bronchial asthma
Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD
Year: 2008
Mometasone/indacaterol/glycopyrronium (MF/IND/GLY) improves lung function and reduces exacerbations in patients with asthma, independent of baseline airflow limitation: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 486s
Year: 2001
Early ICS treatment in subjects with a rapid decline in lung function
Source: Eur Respir J 2001; 18: Suppl. 33, 348s
Year: 2001
A pooled analysis of FEV
1
decline in COPD patients randomized to inhaled corticosteroids or placebo
Source: Eur Respir J 2006; 28: Suppl. 50, 764s
Year: 2006
Long-term predictors of lung function decrease in asthmatics: a 9 year follow-up study
Source: Eur Respir J 2006; 28: Suppl. 50, 145s
Year: 2006
Nasal high flow therapy: The effect on exercise performance in patients with COPD
Source: International Congress 2018 – What’s new in lung function and exercise assessment in COPD?
Year: 2018
CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Intermediate and severe α
1
-antitrypsin deficiency: influence on plasma α
1
-antitrypsin, FEV
1
and risk of COPD. Three meta-anlyses
Source: Eur Respir J 2002; 20: Suppl. 38, 513s
Year: 2002
Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial
Source: International Congress 2018 – Clinical determinants and biomarkers of COPD
Year: 2018
Inhaled corticosteroids and FEV1 decline in asthma: an international cohort study
Source: International Congress 2018 – Asthma in children and adults: long-term aspects
Year: 2018
FVC decline in patients with SSc-ILD by use of anti-acid therapy
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018
Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept